Voyager Q3 net loss widens to $27.9M; cash runway into 2028; NeuroShuttle platform launched

Voyager Therapeutics, Inc.

2025-Q3 EPS reported -$1.57 revenue$25,038,000

Net loss of $27.9M (vs $9.0M in Q3 2024); collaboration revenue fell to $13.4M from $24.6M.
Cash, equivalents, marketable securities $229M; runway extended into 2028.
New collaboration with Transition Bio for TDP-43 small molecules (ALS/FTD); upfront single-digit million, milestones up to $500M.
Introduced ALPL-VYGR-NeuroShuttle nonviral platform; murine data shows >3 weeks brain expression.
Novartis discontinues two discovery programs (rights return); Neurocrine milestone $3M expected Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.